Gilead Sciences — Oct 30, 2025 release

October 30, 2025 3      Guidance and Outlook For the full-year, Gilead expects: (in millions, except per share amounts) October 30, 2025 Guidance Low End High End Comparison to Prior Guidance Product sales $ 28,400  $ 28,700  Previously $28,300 to $28,700 Product sales excluding Veklury $ 27,400  $ 27,700  Previously $27,300 to $27,700 Veklury $ 1,000  $ 1,000  Unchanged Diluted EPS $ 6.65  $ 6.85  Previously $5.85 to $6.15 Non-GAAP diluted EPS $ 8.05  $ 8.25  Previously $7.95 to $8.25 Additional information and a reconciliation between GAAP and non-GAAP financial information for the 2025 guidance is provided in the accompanying tables. The financial guidance is subject to a number of risks and uncertainties. See the Forward-Looking Statements section below. Key Updates Since Our Last Quarterly Release Virology • Announced settlement agreements to resolve Biktarvy patent litigation with generic manufacturers Lupin Ltd., Cipla Ltd. and Laurus Labs Ltd. Under the agreements, the earliest date the three generic manufacturers can market a generic version of full dose Biktarvy in the U.S. is April 1, 2036, subject to standard acceleration provisions. This is more than two years later than our previous loss of exclusivity projection for Biktarvy (December 2033). • Received a strong recommendation for the use of twice-yearly injectable Yeztugo® (lenacapavir) for HIV pre-exposure prophylaxis (“PrEP”) in the new U.S. Centers for Disease Control and Prevention guidelines. • Announced a partn